Ethics of Gene Editing
By Betty Rollin,
KQED Religion & Ethics Newsweekly
| 07. 02. 2015
[with CGS's Marcy Darnovsky]
<span id="XinhaEditingPostion"></span>
A promising new medical technology has the potential to cure many genetic diseases by deleting or replacing defective genes. But ethicist Marcy Darnovsky of the Center for Genetics and Society is concerned about the safety of the technology, the unintended consequences of gene alteration for future generations, and the possibility of wealthy parents using the technology to “enhance” their children, regardless of medical necessity.
Image via WikiMedia Commons.
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...